These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
4. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Drexel H Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899 [TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
8. Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus. Nichols GA; Reynolds K; Olufade T; Kimes TM; O'Keeffe-Rosetti M; Sapp DS; Anzalone D; Fortmann SP Am J Cardiol; 2017 Feb; 119(3):410-415. PubMed ID: 27890243 [TBL] [Abstract][Full Text] [Related]
9. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
14. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]
15. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF; Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743 [TBL] [Abstract][Full Text] [Related]
16. [Risk adapted therapy of vascular diseases--basic therapy of dys- and hyperlipoproteinemia]. Fischer S Z Kardiol; 2005; 94 Suppl 4():IV/24-27. PubMed ID: 16416059 [TBL] [Abstract][Full Text] [Related]
17. [Multimodal therapy of dyslipidemia]. Stahn A; Hanefeld M Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173 [TBL] [Abstract][Full Text] [Related]
19. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects. Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054 [TBL] [Abstract][Full Text] [Related]
20. [Diabetes and lipids]. Lechleitner M; Drexel H Wien Med Wochenschr; 2003; 153(21-22):469-73. PubMed ID: 14679889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]